Kinea Bio is pioneering a dual adeno-associated virus (AAV) vector platform, SIMPLI-GT, designed to deliver therapeutic genes that exceed standard AAV packaging limits. Its lead candidate, KNA-155, aims to restore full-length dysferlin in patients with dysferlinopathy, a progressive muscular dystrophy with no approved treatments. To boost muscle targeting and safety, the company has licensed Solid Biosciences’ next-generation myotropic capsid, AAV-SLB101, as the delivery backbone for systemic administration. Preclinical work has already shown promising efficacy, and upcoming IND-enabling dose-finding and GLP toxicology studies will establish safety, biodistribution and therapeutic windows. The Jain Foundation has committed up to $1.1 million in milestone-based funding to support these studies, giving Kinea Bio initial capital to accelerate toward the clinic. Beyond dysferlinopathy, the firm plans to leverage its SIMPLI-GT platform for additional severe genetic diseases, such as Duchenne muscular dystrophy, through strategic collaborations and continued innovation.

Total raised

$2M

Funding rounds

2

Latest round

Equity

Latest activity

Sep 2025